Earnings summaries and quarterly performance for EXELIXIS.
Executive leadership at EXELIXIS.
Michael M. Morrissey
Detailed
President and Chief Executive Officer
CEO
BH
Brenda Hefti
Detailed
General Counsel
CJ
Christopher J. Senner
Detailed
Executive Vice President and Chief Financial Officer
DT
Dana T. Aftab
Detailed
Executive Vice President, Research and Development
PJ
Patrick J. Haley
Detailed
Executive Vice President, Commercial
Board of directors at EXELIXIS.
DE
David E. Johnson
Detailed
Independent Director
GP
George Poste
Detailed
Independent Director
JL
Jack L. Wyszomierski
Detailed
Independent Director
JA
Julie Anne Smith
Detailed
Independent Director
MC
Maria C. Freire
Detailed
Independent Director
MC
Mary C. Beckerle
Detailed
Independent Director
RL
Robert L. Oliver, Jr.
Detailed
Independent Director
SG
S. Gail Eckhardt
Detailed
Independent Director
SP
Stelios Papadopoulos
Detailed
Independent Chair of the Board
TJ
Tomas J. Heyman
Detailed
Independent Director
Research analysts who have asked questions during EXELIXIS earnings calls.
Asthika Goonewardene
Truist Securities
6 questions for EXEL
Also covers: ALLO, AUTL, BNTX +9 more
Michael Schmidt
Guggenheim Securities
6 questions for EXEL
Also covers: ADAP, ADCT, ARVN +19 more
AV
Ashwani Verma
UBS Group AG
5 questions for EXEL
Also covers: ACAD, ALKS, ALVO +12 more
Jason Gerberry
Bank of America Merrill Lynch
4 questions for EXEL
Also covers: ALKS, AMPH, ARWR +21 more
PL
Peter Lawson
Barclays PLC
4 questions for EXEL
Also covers: ADAP, ARVN, BPMC +15 more
SL
Sudan Loganathan
Stephens Inc.
4 questions for EXEL
Also covers: ADCT, ARVN, BPMC +6 more
YW
Yaron Werber
TD Cowen
4 questions for EXEL
Also covers: ALEC, AMGN, ARGX +14 more
Akash Tewari
Jefferies
3 questions for EXEL
Also covers: ALKS, APLS, ARGX +15 more
Anastasia Parafestas
Jefferies
3 questions for EXEL
Also covers: ALKS
DL
David Lebowitz
Citigroup Inc.
3 questions for EXEL
Also covers: ALNY, ARWR, ASND +11 more
Gregory Renza
RBC Capital Markets
3 questions for EXEL
Also covers: ACAD, ADCT, AGIO +12 more
Sean Laaman
Morgan Stanley & Co.
3 questions for EXEL
Also covers: ACAD, ARGX, AXSM +8 more
ST
Silvan Tuerkcan
Citizens JMP
3 questions for EXEL
Also covers: CLLS, MGNX, NTLA +2 more
SW
Stephen Willey
Stifel Financial Corp.
3 questions for EXEL
Also covers: ABCL, CELC, CGEN +10 more
Andrew Berens
Leerink Partners
2 questions for EXEL
Also covers: AGIO, ARVN, BGNE +6 more
AS
Andy Shea
William Blair
2 questions for EXEL
CM
Chi Meng Fong
BofA Securities
2 questions for EXEL
Also covers: BHC, BYSI, GUTS +2 more
CL
Christopher Lu
SVB Leerink
2 questions for EXEL
Also covers: HOOK
Derek Archila
Wells Fargo
2 questions for EXEL
Also covers: APLS, ARGX, ARVN +9 more
Karishma Raghuram
Goldman Sachs
2 questions for EXEL
Also covers: ALKS, RVNC
Katherine
Morgan Stanley
2 questions for EXEL
Leonid Timashev
RBC Capital Markets
2 questions for EXEL
Also covers: ADCT, ALKS, AXSM +8 more
S
Sarah
TD Cowen
2 questions for EXEL
S
Sean
Oppenheimer & Co. Inc.
2 questions for EXEL
ST
Silvan Turkin
Citizens
2 questions for EXEL
SW
Stephen Willey
Stifel
2 questions for EXEL
Also covers: ABCL, ABEO, CGEN +7 more
TH
Tsan-Yu Hsieh
William Blair & Company
2 questions for EXEL
Also covers: AVIR, CRDF, FGEN +6 more
AH
Andy Hsieh
William Blair & Company
1 question for EXEL
Also covers: ALT, BYSI, CRDF +8 more
AS
Andy Shah
William Blair & Company
1 question for EXEL
Also covers: ALT, CRDF
AN
Anish Nikhanj
RBC Capital Markets
1 question for EXEL
Also covers: APTO, CRMD, FULC +6 more
AV
Ash Verma
UBS
1 question for EXEL
Also covers: ALVO, AVDL, INCY +5 more
Cheng Li
Oppenheimer & Co. Inc.
1 question for EXEL
Also covers: EDIT, INO, NKTR +3 more
CS
Chris Shibutani
Goldman Sachs Group, Inc.
1 question for EXEL
Also covers: ABBV, ALKS, BMY +11 more
ED
Etzer Darout
BMO Capital Markets
1 question for EXEL
Also covers: ARVN, CTMX, GMAB +5 more
Eva Fortea-Verdejo
Wells Fargo Securities
1 question for EXEL
Also covers: KNSA, KYMR, RCUS
Jay Olson
Oppenheimer & Co. Inc.
1 question for EXEL
Also covers: ACAD, AMGN, BIIB +22 more
JC
Joseph Catanzaro
Wolfe Research, LLC
1 question for EXEL
Also covers: AADI, CPRX, CRDF +7 more
SL
Sudan Loganison
Stephens
1 question for EXEL
Recent press releases and 8-K filings for EXEL.
Exelixis Outlines Strategy for Multi-Franchise Growth and Pipeline Advancement at 2025 R&D Day
EXEL
New Projects/Investments
Product Launch
Revenue Acceleration/Inflection
- Exelixis is strategically building towards becoming a top five solid tumor oncology company, expanding beyond its current position as a top 10 U.S. company, with a focus on developing multi-compound, multi-franchise solutions.
- The company projects more than 30% cumulative growth for its Cabozantinib (Cabo) franchise from full year 2023 to full year 2025, supported by existing and two new MET indications.
- Zanzalitinib (Zanza) is a key next-generation molecule, with a New Drug Application (NDA) filed with the FDA based on positive STELLAR-303 trial results in colorectal cancer, which showed a 20% reduction in the risk of death and a median overall survival of 10.9 months for the Zanza plus atezolizumab combination.
- The third-line plus colorectal cancer market represents an estimated $1.5 billion opportunity in the U.S. for Zanza, which is also being advanced through seven ongoing or planned label-enabling studies across various indications, including renal cell carcinoma and adjuvant colorectal cancer.
- Exelixis maintains a productive early-stage pipeline, including three IND candidates (XB010, XB628, XB371), new molecules like XB773 and XL557 advancing towards IND status, and a novel discovery program targeting KRAS with molecular glues and degraders.
Dec 10, 2025, 6:00 PM
Exelixis 2025 R&D Day Highlights Oncology Franchise Growth and Pipeline Milestones
EXEL
Product Launch
New Projects/Investments
Guidance Update
- Exelixis' R&D Day on December 10, 2025, outlined its strategy to become a top 5 solid tumor oncology company with multiple blockbuster products and sustained revenue growth.
- The company reported significant progress since R&D Day 2023, including >30% growth in net product revenues from FY 2023 to a projected ~$2.10-$2.15B in FY 2025, and the first NDA filing for zanzalintinib in Q4-2025 following positive Phase 3 results in 3L+ mCRC.
- Key upcoming milestones for zanzalintinib include a topline readout in mid-2026 for 1L nccRCC (STELLAR 304) and the initiation of a trial in 1L aRCC (LITESPARK-033) in December 2025.
- Exelixis is also advancing its early-stage pipeline, with XB628 (NKG2A x PD-L1 bsAb) having initiated Phase 1 studies in advanced solid tumors in May 2025.
Dec 10, 2025, 6:00 PM
Exelixis Outlines Multi-Franchise Strategy and Pipeline Advancements at 2025 R&D Day
EXEL
New Projects/Investments
Revenue Acceleration/Inflection
- Exelixis is focusing on building a multi-compound, multi-franchise company, with a strategic emphasis on kidney cancer, neuroendocrine tumors, and colorectal cancer.
- The CABO franchise is projected to achieve more than 30% cumulative growth from full year 2023 to full year 2025, supported by two new CABOMETYX indications in the MET space.
- Zanzalitinib (Zanza) is positioned as the next potential franchise molecule, with positive top-line results from the STELLAR-303 trial leading to an FDA filing, and seven ongoing or planned label-enabling studies.
- The company's pipeline includes XB628, a novel bispecific IO-focused molecule targeting PD-L1 and NKG2A in early clinical stage, and XB371, a tissue factor-targeting ADC for colorectal cancer, both showing high potential.
- The STELLAR-303 trial for Zanzalitinib plus atezolizumab in colorectal cancer met its dual primary endpoint, demonstrating a 20% reduction in the risk of death in the ITT population.
Dec 10, 2025, 6:00 PM
Exelixis Outlines Strategy for Multi-Franchise Growth and Pipeline Expansion at 2025 R&D Day
EXEL
New Projects/Investments
Product Launch
Guidance Update
- Exelixis aims to become a top five solid tumor oncology company, building on its current position as a top 10 U.S. solid tumor oncology company in 2024, by developing a multi-compound, multi-franchise pipeline focused on improving the standard of care for cancer patients.
- The company projects more than 30% cumulative growth in CABOMETYX product revenues from full year 2023 to full year 2025, driven by continued outsized growth and two new neuroendocrine tumor (NET) indications approved in March 2025.
- Exelixis has filed an NDA for zanzalitinib (zanza) based on positive top-line results from the STELLAR-303 trial, which demonstrated a 20% reduction in the risk of death in non-MSI high colorectal cancer patients, representing an estimated $1.5 billion market opportunity in the third-line plus setting.
- The early-stage pipeline includes three IND candidates (XB010, XB628, XB371) and new molecules like XB773 (ADC) and XL557 (SSTR2 agonist) advancing towards IND status, with a strategic focus on kidney cancer, NET, and colorectal cancer franchises.
Dec 10, 2025, 6:00 PM
Exelixis Reports Strong Q3 2025 Results and Advances Key Pipeline Products
EXEL
Product Launch
New Projects/Investments
Revenue Acceleration/Inflection
- Exelixis reported strong Q3 2025 financial results, with $543 million in net product revenue and total revenues just under $600 million, largely due to the success of Cabometyx.
- The launch of Cabometyx in neuroendocrine tumors (NET) is performing strongly, showing 50% quarter-over-quarter growth and achieving over 40% market share in new patient starts, with sales expected to surpass $100 million for the year.
- The company plans to submit an NDA for its key pipeline product, Zanzalintinib (Zanza), in colorectal cancer by the end of 2025, targeting a $1 billion opportunity in the US.
- Exelixis is also advancing Zanza in other indications, with an upcoming data release for non-clear-cell RCC in H1 2026 and a Phase II/III study in neuroendocrine tumors, aiming to build new oncology franchises.
Nov 10, 2025, 3:30 PM
Exelixis Reports Strong Q3 2025 Results and Pipeline Progress
EXEL
Earnings
Product Launch
New Projects/Investments
- Exelixis reported strong Q3 2025 financial performance, with net product revenue of $543 million and total revenues just under $600 million.
- The Cabometyx launch for neuroendocrine tumors (NET) is exceeding expectations, showing 50% quarter-over-quarter growth and capturing over 40% market share in new patient starts, with projected incremental full-year sales exceeding $100 million.
- The company is advancing its pipeline with a planned NDA submission for Zanzalintinib (Zanza) by end of 2025 for colorectal cancer, and is exploring its potential in non-clear-cell renal cell carcinoma (RCC) and in combination with Merck's Belzutifan for RCC.
Nov 10, 2025, 3:30 PM
Exelixis Discusses Strong Q3 2025 Performance and Pipeline Progress
EXEL
Earnings
Product Launch
New Projects/Investments
- Exelixis reported strong Q3 2025 financial results, with $543 million in net product revenue and total revenues just under $600 million.
- The launch of Cabometyx in neuroendocrine tumors (NET) is performing well, achieving 50% Q over Q growth and over 40% market share in new patient starts, with full-year sales projected to exceed $100 million.
- Zanzalintinib (Zanza) is a key pipeline asset with an NDA submission planned by year-end, targeting a $1 billion opportunity in the US for colorectal cancer (CRC).
- Further opportunities for Zanza include upcoming data in non-clear-cell RCC in the first half of next year, which accounts for 15%-20% of the overall RCC population, and a partnership with Merck for a combination in RCC.
- The company is strategically expanding its commercial footprint, particularly in the GI space, to support current and future product launches.
Nov 10, 2025, 3:30 PM
Exelixis Reports Strong Q3 2025 Results, Cabozantinib Growth, and Positive Zanzalintinib Trial Data
EXEL
Earnings
Guidance Update
Share Buyback
- Exelixis reported Q3 2025 total revenues of $598 million and GAAP diluted earnings per share (EPS) of $0.69, with non-GAAP diluted EPS of $0.78.
- The Cabozantinib U.S. franchise net product revenues grew approximately 14% year-over-year to $543 million in Q3 2025, and global net product revenues were $739 million. The company expects to exceed $100 million in revenue for the neuroendocrine tumor (NET) indication in 2025.
- Zanzalintinib (Zanza) showed positive results from the STELLAR-303 trial in colorectal cancer (CRC), demonstrating a 20% reduction in the risk of death in the ITT population, and the company intends to file for regulatory approval based on these results.
- The company's board authorized an additional $750 million share repurchase program on October 31, 2025, expiring at the end of 2026, following the repurchase of approximately $99 million in Q3 2025.
- Exelixis updated its full-year 2025 guidance, narrowing total revenue to between $2.3 billion and $2.35 billion and net product revenue to between $2.1 billion and $2.15 billion, while also lowering R&D expense guidance to $850-$900 million.
Nov 4, 2025, 10:00 PM
Exelixis Reports Strong Q3 2025 Results, Updates Full-Year Guidance, and Authorizes New Share Repurchase Program
EXEL
Earnings
Guidance Update
Share Buyback
- Exelixis reported Q3 2025 total revenues of $598 million, with GAAP diluted earnings per share of $0.69 and non-GAAP diluted earnings per share of $0.78.
- The Cabozantinib franchise saw US net product revenues increase 14% year-over-year to $543 million in Q3 2025, and the neuroendocrine tumor (NET) indication is projected to exceed $100 million in revenue for 2025.
- Zanzalintinib (Zanza) showed positive results from the Stellar-303 trial in colorectal cancer, demonstrating a 20% reduction in the risk of death in the ITT population, with an NDA filing intended for December.
- The company updated its full-year 2025 financial guidance, narrowing total revenue to between $2.3 billion and $2.35 billion and net product revenue to between $2.1 billion and $2.15 billion.
- Exelixis' board authorized an additional $750 million share repurchase program on October 31, 2025, following $99 million in share repurchases during Q3 2025.
Nov 4, 2025, 10:00 PM
Exelixis Reports Strong Q3 2025 Results, Updates Full-Year Guidance, and Announces Positive Zanzalintinib Trial Data
EXEL
Earnings
Guidance Update
Share Buyback
- Exelixis reported Q3 2025 total revenues of $598 million and GAAP diluted EPS of $0.69, with non-GAAP diluted EPS of $0.78.
- The company updated its full-year 2025 financial guidance, narrowing total revenue to $2.3 billion to $2.35 billion and net product revenue to $2.1 billion to $2.15 billion, both to the upper end of previous guidance. R&D expense guidance was lowered to $850 million to $900 million.
- Cabozantinib US net product revenues grew 14% year-over-year to $543 million in Q3 2025, contributing to global Cabo franchise net product revenues of $739 million. The neuroendocrine tumor (NET) indication is expected to exceed $100 million in revenue for 2025.
- Exelixis announced positive results from the Stellar-303 trial for Zanzalintinib in colorectal cancer, demonstrating a 20% reduction in the risk of death in the ITT population, and plans to file an NDA in December 2025, pending government reopening.
- The board authorized an additional $750 million share repurchase program, following the repurchase of $99 million in Q3 2025.
Nov 4, 2025, 10:00 PM
Quarterly earnings call transcripts for EXELIXIS.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more